A detailed history of Verition Fund Management LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 56,909 shares of AVIR stock, worth $181,539. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,909
Previous 65,976 13.74%
Holding current value
$181,539
Previous $218,000 12.84%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.17 - $4.02 $28,742 - $36,449
-9,067 Reduced 13.74%
56,909 $190,000
Q2 2024

Aug 14, 2024

BUY
$3.31 - $4.04 $218,380 - $266,543
65,976 New
65,976 $218,000
Q3 2023

Nov 14, 2023

BUY
$3.0 - $3.79 $68,862 - $86,995
22,954 New
22,954 $68,000
Q3 2021

Nov 15, 2021

SELL
$21.33 - $35.06 $306,618 - $503,987
-14,375 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$19.22 - $59.08 $276,287 - $849,275
14,375 New
14,375 $309,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.